Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
19.26
-0.45 (-2.28%)
At close: Nov 7, 2025, 4:00 PM EST
19.29
+0.03 (0.16%)
After-hours: Nov 7, 2025, 7:58 PM EST
Apellis Pharmaceuticals Revenue
Apellis Pharmaceuticals had revenue of $458.58M in the quarter ending September 30, 2025, with 132.98% growth. This brings the company's revenue in the last twelve months to $1.02B, up 42.11% year-over-year. In the year 2024, Apellis Pharmaceuticals had annual revenue of $781.37M with 97.02% growth.
Revenue (ttm)
$1.02B
Revenue Growth
+42.11%
P/S Ratio
2.38
Revenue / Employee
$1,431,545
Employees
710
Market Cap
2.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 781.37M | 384.78M | 97.02% |
| Dec 31, 2023 | 396.59M | 321.17M | 425.83% |
| Dec 31, 2022 | 75.42M | 8.86M | 13.31% |
| Dec 31, 2021 | 66.56M | -184.08M | -73.44% |
| Dec 31, 2020 | 250.65M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
APLS News
- 2 days ago - Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 8 days ago - Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 18 days ago - New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week - GlobeNewsWire
- 22 days ago - Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders - Seeking Alpha
- 2 months ago - Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript) - Seeking Alpha